$158.30
+1.91 (+1.22%)
Last updated: May 31, 2026 08:06
Fundamentals Overview
Neurocrine Biosciences, Inc. is near the high of its 52-week range with moderate valuation, trading relatively flat today.
Valuation moderate
Intrinsic value (DCF)
+209.3% upside vs price
Profitability
Risk (Beta)
0.34 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +209.3% upside vs price · Analyst grade: A · 3M vs S&P 500: +11.6% · 3M vs Healthcare sector: +26%
Pressures (Sell):
Sentiment weakening (1 downgrade)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: A. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 13, Equal Weight: 3, Market Perform: 1, Outperform: 7, Overweight: 6.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $489.70; current price is $158.30. That’s a +209.3% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 24.48 |
| DCF value (model) | $489.70 (209.3% upside) |
| PEG (TTM) | 0.21 |
| P/B (TTM) | 4.67 |
| P/S (TTM) | 5.13 |
| P/FCF (TTM) | 19.15 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 2.93 |
| Quick Ratio (TTM) | 2.85 |
| Cash Ratio (TTM) | 0.32 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 21.55% |
| Gross margin (TTM) | 98.17% |
| Operating margin (TTM) | 25.19% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for NBIX.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| RBC Capital | maintain | Outperform | Outperform | 2026-05-29 |
| JP Morgan | maintain | Overweight | Overweight | 2026-05-08 |
| Truist Securities | maintain | Buy | Buy | 2026-05-07 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-05-06 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-05-06 |
| Citigroup | maintain | Buy | Buy | 2026-05-06 |
| RBC Capital | maintain | Outperform | Outperform | 2026-05-06 |
| Wedbush | maintain | Outperform | Outperform | 2026-05-06 |
| Guggenheim | maintain | Buy | Buy | 2026-05-06 |
| Leerink Partners | maintain | Outperform | Outperform | 2026-04-22 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-04-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-04-07 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-04-07 |
| Citigroup | maintain | Buy | Buy | 2026-04-07 |
| Wedbush | maintain | Outperform | Outperform | 2026-04-07 |
| Needham | maintain | Buy | Buy | 2026-04-06 |
| JP Morgan | maintain | Overweight | Overweight | 2026-03-12 |
| JP Morgan | maintain | Overweight | Overweight | 2026-02-17 |
| Truist Securities | maintain | Buy | Buy | 2026-02-17 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-13 |
| Wedbush | maintain | Outperform | Outperform | 2026-02-12 |
| RBC Capital | maintain | Outperform | Outperform | 2026-02-12 |
| Citigroup | maintain | Buy | Buy | 2026-02-12 |
| BMO Capital | maintain | Market Perform | Market Perform | 2026-02-12 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-12 |
| Needham | maintain | Buy | Buy | 2026-02-12 |
| UBS | maintain | Buy | Buy | 2026-01-23 |
| JP Morgan | maintain | Overweight | Overweight | 2026-01-12 |
| Morgan Stanley | downgrade | Overweight | Equal Weight | 2026-01-08 |
| Truist Securities | maintain | Buy | Buy | 2026-01-08 |